Cover Image
市場調查報告書

亞太地區的骨質疏鬆症治療市場:2022年

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

出版商 GBI Research 商品編碼 366603
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的骨質疏鬆症治療市場:2022年 Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies
出版日期: 2016年07月04日 內容資訊: 英文 131 Pages
簡介

亞太地區的骨質疏鬆症市場規模預測將從2015年的45億美元,到2022年以7.8%的年複合成長率擴大到77億美元。

本報告提供亞太地區的骨質疏鬆症治療藥市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等,提供著有系統的資訊。

第1章 目錄

第2章 簡介

  • 病的簡介
  • 流行病學
  • 症狀
  • 病因·病理學
  • 診斷
  • 分期
  • 預後
  • 治療選擇
    • 治療流程
    • 藥理學性治療
    • 非藥理學性治療
    • 練習
    • 飲食療法干預

第3章 上市產品

  • 概要
  • 雙膦酸鹽
  • Dual-Acting Non-Bisphosphonates
  • 選擇性雌激素受體調節藥
  • NFKB活性化受體配體 (RANKL) 抑制劑
  • Calcitonins
  • Parathyroid Hormone
  • 上市產品的有效性·安全性比較

第4章 開發平台分析

  • 概要
  • 開發平台:開發階段,分子類型,給藥途徑及計劃類別
  • 開發平台:分子標的別
  • 開發平台有潛力開發平台候補藥
  • 開發中產品的有效性·安全性比較
  • 產品競爭力的組成架構

第5章 臨床實驗分析

  • 失敗率
    • 整體失敗率
    • 失敗率:各期·各分子類型
    • 失敗率:各期·分子標的別
  • 臨床實驗期間
    • 各分子類型
    • 各分子標的
  • 臨床實驗規模
    • 每個產品的病患註冊:分子類型,分子標的,各開發階段
    • 每個實驗的病患註冊:
  • 臨床實驗標準比較分析

第6章 複數方案預測

  • 地區市場
  • 亞太地區市場
  • 印度
    • 治療利用模式
    • 治療的年度成本
    • 市場規模
  • 中國
  • 澳洲
  • 韓國
  • 日本

第7章 促進要素·障礙

  • 促進要素
    • 罹患率的增加
    • 老年人健康保險範圍的擴大
    • 國民·政策籌劃者的認知度提升
    • 有潛力後期開發中產品治療範例可變更
  • 障礙
    • 專利到期·學名藥的侵蝕
  • 迫近
    • 低診斷·治療率
    • 現有藥物的競爭、其他

第8章 契約·策略性討論事項

  • 授權契約
  • 共同開發契約

第9章 附錄

圖表

目錄
Product Code: GBIHC410MR

Executive Summary

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

Scope

The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.

  • Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
  • How will immunotherapies such as Prolia contribute to growth?
  • What effect will the patent expirations of currently branded therapies have on market value?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.

  • Which molecular targets appear most frequently in the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?
  • Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.

  • How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
  • How could changes in risk factors such as aging population, calcium and vitamin D deficiency influence the market?

Various drivers and barriers will influence the market over the forecast period.

  • What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
  • Which factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to-

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, - and how they will compete with other therapies.
  • Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Disease Stages
  • 2.7. Prognosis
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Pharmacological Treatments
    • 2.8.3. Non-Pharmacological Treatments
    • 2.8.4. Exercise
    • 2.8.5. Dietary Interventions

3. Marketed Products

  • 3.1. Overview
  • 3.2. Bisphosphonates
    • 3.2.1. Risedronate - Warner Chilcott
    • 3.2.2. Alendronate - Merck & Co
    • 3.2.3. Boniva (ibandronate) - Roche
    • 3.2.4. Zoledronic Acid - Novartis
    • 3.2.5. Recalbon/Bonoteo (minodronate) - Ono and Astellas Pharma
    • 3.2.6. Etidronate - Procter & Gamble and Sumitomo Pharmaceuticals
  • 3.3. Dual-Acting Non-Bisphosphonates
    • 3.3.1. Strontium Ranelate - Servier
  • 3.4. Selective Estrogen Receptor Modulators
    • 3.4.1. Evista (raloxifene) - Eli Lilly
    • 3.4.2. Viviant (bazedoxifene) - Ligand and Pfizer
  • 3.5. Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Inhibitor
    • 3.5.1. Prolia (denosumab) - Amgen
  • 3.6. Calcitonins
    • 3.6.1. Calcitonin-salmon
  • 3.7. Parathyroid Hormone
    • 3.7.1. Forteo (teriparatide) - Eli Lilly
  • 3.8. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Candidates
    • 4.4.1. Romosozumab (AMG-785) - Amgen
    • 4.4.2. Abaloparatide-SC (BA-058-SC) - Radius Health
    • 4.4.3. Odanacatib (MK-0822) - Merck & Co
    • 4.4.4. Uni-PTH - Uni-Bio Science
  • 4.5. Comparative Efficacy and Safety of Pipeline Products
  • 4.6. Product Competitiveness Framework

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Duration
    • 5.2.1. Clinical Trial Duration by Molecule Type
    • 5.2.2. Clinical Trial Duration by Molecular Target
  • 5.3. Clinical Trial Size
    • 5.3.1. Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
    • 5.3.2. Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
  • 5.4. Competitive Clinical Trials Metrics Analysis

6. Multi-Scenario Forecast

  • 6.1. Geographical Markets
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Rising Prevalence
    • 7.1.2. Increasing Health Insurance Coverage for Aged Population
    • 7.1.3. Increasing Public and Policymaker Awareness
    • 7.1.4. Promising Late-Stage Pipeline Products can Change the Treatment Paradigm
  • 7.2. Barriers
    • 7.2.1. Impending Patent Cliffs and Generic Erosion
    • 7.2.2. Low Diagnosis and Treatment Rates
    • 7.2.3. Non-Availability or Lack of Benefits for Combination Anabolic and Antiresorptive Therapies
    • 7.2.4. Competition from Traditional Medicines

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.1.4. Key Licensing Deals
  • 8.2. Co-Development Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type, and Molecular Target
    • 8.2.4. Key Co-Development Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Stage of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/ Clinical Trial Authorization-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Market Forecasts to 2021
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. Bibliography
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Osteoporosis Therapeutics Market, Classical Case of Osteoporosis with Respect to Age
  • Table 2: Osteoporosis Therapeutics Market, Common Types of Fracture in Osteoporosis
  • Table 3: Osteoporosis Therapeutics Market, Diagnosis Tests for Osteoporosis
  • Table 4: Osteoporosis Therapeutics Market, T-Score Ranges for Determination of BMD
  • Table 5: Osteoporosis Therapeutics Market, Clinical Stage Characteristics
  • Table 6: Osteoporosis Therapeutics Market, Clinical Types of Osteoporosis
  • Table 7: Osteoporosis Therapeutics Market, Characteristics of Type 1 and 2 Primary Osteoporosis
  • Table 8: Osteoporosis Therapeutics Market, Causes of Secondary Osteoporosis
  • Table 9: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
  • Table 10: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
  • Table 11: Osteoporosis Therapeutics Market, Global, All Pipeline Products, IND/CTA-Filed, 2016
  • Table 12: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
  • Table 13: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
  • Table 14: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
  • Table 15: Osteoporosis Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2016
  • Table 16: Osteoporosis Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
  • Table 17: Osteoporosis Therapeutics Market, India, Market Forecast, 2015-2022
  • Table 18: Osteoporosis Therapeutics Market, China, Market Forecast, 2015-2022
  • Table 19: Osteoporosis Therapeutics Market, Australia, Market Forecast, 2015-2022
  • Table 20: Osteoporosis Therapeutics Market, South Korea, Market Forecast, 2015-2022
  • Table 21: Osteoporosis Therapeutics Market, Japan, Market Forecast, 2015-2022

List of Figures

  • Figure 1: Osteoporosis Therapeutics Market, Treatment Algorithm of Osteoporosis
  • Figure 2: Osteoporosis Therapeutics Market, Comparative Efficacy and Safety Heat Map for Marketed Products for the Treatment of Osteoporosis
  • Figure 3: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Treatment of Osteoporosis in Men
  • Figure 4: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Treatment of Glucocorticoid-Induced Osteoporosis
  • Figure 5: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Marketed Products for the Prevention of Osteoporosis in Postmenopausal Women
  • Figure 6: Pipeline for Osteoporosis Therapeutics, Global, 2016
  • Figure 7: Pipeline for Osteoporosis Therapeutics by Molecular Target, Global, 2016
  • Figure 8: Pipeline for Osteoporosis Therapeutics by Molecular Target and Stage of Development, Global, 2016
  • Figure 9: Osteoporosis Therapeutics Market, Asia-Pacific, Romosozumab Market Forecast ($m), 2018-2022
  • Figure 10: Osteoporosis Therapeutics Market, Asia-Pacific, Abaloparatide Market Forecast ($m), 2018-2022
  • Figure 11: Osteoporosis Therapeutics Market, Asia-Pacific, Odanacatib Market Forecast ($m), 2018-2022
  • Figure 12: Osteoporosis Therapeutics Market, Asia-Pacific, Uni-PTH Market Forecast ($m), 2020-2021
  • Figure 13: Osteoporosis Therapeutics Market, Comparative Efficacy Heat Map for Pipeline Products
  • Figure 14: Osteoporosis Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2016
  • Figure 15: Osteoporosis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2015
  • Figure 16: Osteoporosis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2015
  • Figure 17: Osteoporosis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2015
  • Figure 18: Osteoporosis Therapeutics, Global, Clinical Trial Duration by Molecule Type, 2006-2015
  • Figure 19: Osteoporosis Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015
  • Figure 20: Osteoporosis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015
  • Figure 21: Osteoporosis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015
  • Figure 22: Osteoporosis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type, 2006-2015
  • Figure 23: Osteoporosis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015
  • Figure 24: Osteoporosis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 25: Osteoporosis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 26: Osteoporosis Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022
  • Figure 27: Osteoporosis Therapeutics Market, India, Treatment Patterns (million), 2015-2022
  • Figure 28: Osteoporosis Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
  • Figure 29: Osteoporosis Therapeutics Market, India, Market Size ($m), 2015-2022
  • Figure 30: Osteoporosis Therapeutics Market, China, Treatment Patterns (million), 2015-2022
  • Figure 31: Osteoporosis Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
  • Figure 32: Osteoporosis Therapeutics Market, China, Market Size ($m), 2015-2022
  • Figure 33: Osteoporosis Therapeutics Market, Australia, Treatment Patterns ('000), 2015-2022
  • Figure 34: Osteoporosis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
  • Figure 35: Osteoporosis Therapeutics Market, Australia, Market Size ($m), 2015-2022
  • Figure 36: Osteoporosis Therapeutics Market, South Korea, Treatment Patterns ('000), 2015-2022
  • Figure 37: Osteoporosis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
  • Figure 38: Osteoporosis Therapeutics Market, South Korea, Market Size ($m), 2015-2022
  • Figure 39: Osteoporosis Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
  • Figure 40: Osteoporosis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
  • Figure 41: Osteoporosis Therapeutics Market, Japan, Market Size ($m), 2015-2022
  • Figure 42: Osteoporosis Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2015
  • Figure 43: Osteoporosis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
  • Figure 44: Osteoporosis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
  • Figure 45: Osteoporosis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 46: Osteoporosis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2015
  • Figure 47: Osteoporosis Therapeutics Market, Global, Co-development Deals by Region, 2006-2015
  • Figure 48: Osteoporosis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
  • Figure 49: Osteoporosis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 50: Osteoporosis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015
Back to Top